drs. M. Nijland

m.nijland umcg.nl


  1. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

    Kersten, M. J., Driessen, J., Zijlstra, J. M., Plattel, W. J., Morschhauser, F., Lugtenburg, P. J., Brice, P., Hutchings, M., Gastinne, T., Liu, R., Burggraaff, C. N., Nijland, M., Tonino, S. H., Arens, A. I. J., Valkema, R., van Tinteren, H., Lopez-Yurda, M., Diepstra, A., De Jong, D. & Hagenbeek, A., 9-Apr-2020, In : Haematologica.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

    de Jong, M. R. W., Langendonk, M., Reitsma, B., Herbers, P., Lodewijk, M., Nijland, M., van den Berg, A., Ammatuna, E., Visser, L. & van Meerten, T., Jan-2020, In : Therapeutic advances in hematology. 11, p. 2040620719898373 14 p., 2040620719898373.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (41) »

Press / Media
  1. Medtalks:Diffuus Grootcellig B-cellymfoom 2018

    Marcel Nijland


    1 Media contribution

    Press/Media: Expert CommentProfessional

View all (1) »

ID: 59823087